p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.

To determine whether variation in the level of expression of p16 and p21WAF1 (p21) is associated with critical stages in cutaneous melanoma development or progression, the expression of these antigens was analyzed by immunohistochemistry in 110 benign and malignant melanocytic lesions. Differential expression of p16 protein has been reported in cutaneous melanocytic lesions, with loss of expression associated with the invasive stage of tumor development. Expression of p16 was seen in 31 of 35 benign melanocytic tumors (89%), 11 of 12 in situ melanomas (92%), 19 of 38 invasive primary melanomas (50%), and 16 of 25 metastatic melanomas (64%). There was a significant difference in the expression level of p16 observed in in situ versus invasive primary melanomas (p = 0.006), which is consistent with loss of normal p16 activity occurring in association with malignant tumor invasion. Overall, p21 levels were found to be low or undetectable in the majority of benign lesions, with greater p21 expression seen in malignant tumors. p21 was expressed in 28% of nevi, 60% of in situ melanomas, 61% of invasive melanomas, and 48% of metastatic melanomas. Among primary invasive tumors, the frequency of p21 expression increased with level of invasion (p < 0.01) and with increasing thickness (p < 0.01). However, differences in p21 expression were not clearly related to a particular stage of melanoma development.

[1]  D. English,et al.  Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. , 1998, The American Journal of dermatopathology.

[2]  R. Maestro,et al.  p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression , 1997, International journal of cancer.

[3]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[4]  R. Kerbel,et al.  Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. , 1996, The American journal of pathology.

[5]  C. Moskaluk,et al.  p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. , 1996, Human pathology.

[6]  S. Semba,et al.  EXPRESSION OF CYCLIN‐DEPENDENT KINASE INHIBITOR p21WAF1/CIP1 IN NON‐NEOPLASTIC MUCOSA AND NEOPLASIA OF THE STOMACH: RELATIONSHIP WITH p53 STATUS AND PROLIFERATIVE ACTIVITY , 1996, The Journal of pathology.

[7]  U. Kees,et al.  Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. , 1996, Oncogene.

[8]  E. Hovig,et al.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.

[9]  C. Shields,et al.  Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma , 1996, International journal of cancer.

[10]  T. Saida,et al.  Immunohistochemical detection of CDK4 and 9 16INK4 proteins in cutaneous malignant melanoma , 1996, The British journal of dermatology.

[11]  M. Inganäs,et al.  Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. , 1996, British Journal of Cancer.

[12]  Z. Su,et al.  Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. , 1995, Oncogene.

[13]  R. Kratzke,et al.  Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.

[14]  B. Peters,et al.  Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.

[15]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[16]  R. Hruban,et al.  p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. , 1995, The American journal of pathology.

[17]  X. Estivill,et al.  Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. , 1995, American journal of human genetics.

[18]  N. Hayward,et al.  Mutations and defective expression of the WAF1 p21 tumour‐suppressor gene in malignant melanomas , 1995, Melanoma research.

[19]  C. Bartram,et al.  Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.

[20]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[21]  K. Kinzler,et al.  Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. , 1995, Cancer research.

[22]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[23]  F. Mandelli,et al.  Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. , 1995, Blood.

[24]  R. Eeles,et al.  Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. , 1995, The American journal of pathology.

[25]  B. Vogelstein,et al.  Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.

[26]  M. Pagano,et al.  Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. , 1994, Cancer research.

[27]  Ashutosh Kumar Singh,et al.  Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. , 1994, Cancer research.

[28]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[29]  Y. Xiong,et al.  Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. , 1994, Oncogene.

[30]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[31]  D. Elder,et al.  Chromosome 9 deletion in sporadic and familial melanomas in vivo. , 1994, Oncogene.

[32]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[33]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[34]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[35]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[36]  D. Beach,et al.  Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. , 1993, Molecular biology of the cell.